Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-FLOT-TNT for resectable gastroesophageal adenocarcinoma
2026-525185-21-00Phase 2Authorised
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Aug 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, docetaxel, oxaliplatin, fluorouracil and folinic acid in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Pathological complete response rate. Planned start Aug 2026; status: authorised.
02
Drugs
durvalumabdocetaxeloxaliplatinfluorouracilfolinic acid
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2026-525185-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525185-21-00.